Tomas Navratil Biography and Net Worth

Chief Development Officer of Glaukos

Dr. Navratil has served as our chief development officer since April 2022. He previously served as our senior vice president, research and development since joining Glaukos in October 2020. Dr. Navratil has 20+ years of experience in ophthalmic drug and medical device R&D and regulatory affairs spanning new chemical entities, novel medical devices, sustained release drugs and novel routes of administration, Phase 1-4 clinical programs, and regulatory submissions to the U.S. Food & Drug Administration, the European Medicines Agency, and regulatory authorities in Asia Pacific. From 2017 to October 2020, Dr. Navratil served in several leadership positions at the Nicox group, including general manager of Nicox Ophthalmics, Inc. and executive vice president and global head of R&D for Nicox S.A. Prior to joining Nicox, he served as senior vice president of development at Envisia Therapeutics. Prior to Envisia Therapeutics, Dr. Navratil held several director-level positions in drug discovery, clinical research and development, and medical affairs at Liquidia Technologies, Parion Sciences and Inspire Pharmaceuticals. He has been issued multiple patents and authored multiple publications on ocular and pulmonary drug delivery and product development. Dr. Navratil was a Morehead Scholar and received his B.S. and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.

What is Tomas Navratil's net worth?: The estimated net worth of Tomas Navratil is at least $7.73 million as of February 14th, 2025. Dr. Navratil owns 72,437 shares of Glaukos stock worth more than $7,730,477 as of March 26th. This net worth estimate does not reflect any other investments that Dr. Navratil may own. Additionally, Dr. Navratil receives an annual salary of $866,180.00 as Chief Development Officer at Glaukos. Learn More about Tomas Navratil's net worth.
How old is Tomas Navratil?: Dr. Navratil is currently 47 years old. There are 5 older executives and no younger executives at Glaukos. The oldest executive at Glaukos is Ms. Jane E. Rady, Senior Vice President of Corporate Strategy & Business Development, who is 76 years old. Learn More on Tomas Navratil's age.
What is Tomas Navratil's salary?: As the Chief Development Officer of Glaukos Co., Dr. Navratil earns $866,180.00 per year. The highest earning executive at Glaukos is Mr. Joseph E. Gilliam, President & COO, who commands a salary of $1,180,000.00 per year. Learn More on Tomas Navratil's salary.
How do I contact Tomas Navratil?: The corporate mailing address for Dr. Navratil and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at investors@glaukos.com. Learn More on Tomas Navratil's contact information.
Has Tomas Navratil been buying or selling shares of Glaukos?: Over the course of the past ninety days, Tomas Navratil has sold $502,630.24 in Glaukos stock. Most recently, Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a transaction totalling $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. Learn More on Tomas Navratil's trading history.
Who are Glaukos' active insiders?: Glaukos' insider roster includes Thomas Burns (CEO), Mark Foley (Director), Joseph Gilliam (CFO), Gilbert Kliman (Director), Tomas Navratil (Chief Development Officer), Marc Stapley (Director), Alex Thurman (CFO), and Aimee Weisner (Director). Learn More on Glaukos' active insiders.
Are insiders buying or selling shares of Glaukos?: During the last year, insiders at the medical instruments supplier sold shares 24 times. They sold a total of 143,994 shares worth more than $16,595,020.83. The most recent insider tranaction occured on February, 14th when insider Tomas Navratil sold 3,416 shares worth more than $502,630.24. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.
Information on this page was last updated on 2/14/2025.

Tomas Navratil Insider Trading History at Glaukos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/14/2025	Sell	3,416	$147.14	$502,630.24	72,437

Tomas Navratil Buying and Selling Activity at Glaukos

Glaukos Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $106.72

$105.78

$108.41

50 Day Range

MA: $133.61

$96.32

$161.55

2 Week Range

Now: $106.72

$87.59

$163.71

Volume

526,460 shs

Average Volume

585,469 shs

Market Capitalization

$6.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Tomas Navratil Biography and Net Worth

What is Tomas Navratil's net worth?

How old is Tomas Navratil?

What is Tomas Navratil's salary?

How do I contact Tomas Navratil?

Has Tomas Navratil been buying or selling shares of Glaukos?

Who are Glaukos' active insiders?

Are insiders buying or selling shares of Glaukos?